Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹1,719.50
17.00 (1.00%)
High VOLATILITY
As on 10 Jul 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹2.30K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
22.1
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹424+305.5%
52W High₹2,044.3-15.9%
Current Price
₹1,719.50
Circuit Limits (5%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,633.52
Upper Circuit₹1,805.48
Reference Price
₹1,719.50
Investment Checklist
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Composite score 37.33 (BUY) with 87.3% confidence
10/20 Bearish Cross detected 2 day(s) ago
EMA(20) Crossover: Price crossed above EMA(20): Fresh bullish momentum signal.
SuperTrend(10,3): Price above SuperTrend (Industry Standard (Swing/Medium-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Confidence
87%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
1704.84
EMA50
1496.24
EMA200
992.7
Price Action
DOWNTREND
BEARISH
Higher Highs3
Higher Lows2
Lower Highs6
Lower Lows7
Support & Resistance Levels
Resistance (Above)
₹1943.80
₹2044.30
Support (Below)
₹1630.00
₹1088.80
₹1027.95
₹944.75
₹904.72
Volume Analysis
TrendDECREASING
Change-31.10%
Unusual VolumeNo
Recent MA Crossovers
10/20 Bearish Cross
2 days ago
SELL
Stop Loss Levels
Fixed Risk
1% Risk₹1702.31
3% Risk₹1667.91
5% Risk₹1633.52
7% Risk (Custom)
₹1599.13Technical Levels
1x ATR (Volatility)₹1616.90
2x ATR (Swing)₹1514.30
3x ATR (Trend)₹1411.70
Immediate Support₹1630.00
Moving Averages
EMA 20 (Medium-term)₹1704.84
EMA 50 (Trend)₹1496.24
EMA 200 (Long-term)₹992.70
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹194.4 Cr | ₹131.9 Cr | ₹192.8 Cr | ₹180.3 Cr |
| Net Profit | ₹21 Cr | ₹9.6 Cr | ₹20.1 Cr | ₹25.6 Cr |
| EPS | — | ₹7.18 | ₹15.06 | ₹19.14 |
| Operating Profit | ₹35.8 Cr | ₹18.8 Cr | ₹32.7 Cr | ₹40 Cr |
ROE
8.08%
ROCE
12.78%
Debt/Equity
0.00
Current Ratio
3.31
OPM
22.21%
NPM
14.19%
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Venus Remedies Limited | ₹1,719.50 | +1.00% | 22.1 | ₹2.30K Cr small Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 13 Sept 2024 | Annual General Meeting | AGM |
| 17 Aug 2023 | Annual General Meeting | AGM |
| 11 Aug 2022 | Annual General Meeting | AGM |
| 09 Sept 2021 | Annual General Meeting | AGM |
| 24 Nov 2020 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
| Date | Purpose | Type |
|---|---|---|
| 20 Jul 2026 | Financial Results/Other business matters | RESULTS |
Latest News
News for VENUSREM
View AllNEWS
positive
Business Standard - Markets 45d ago
Venus Remedies consolidated net profit rises 126.19% in the March 2026 quarter
Sales rise 33.05% to Rs 259.40 crore
VENUSREMHealthcare
NEWS
positive
Business Standard - Markets 45d ago
Venus Remedies standalone net profit rises 193.78% in the March 2026 quarter
Sales rise 31.65% to Rs 259.01 crore
VENUSREMHealthcare
positive
ET Markets - Industry 49d ago
Venus Remedies gets Saudi FDA approval for speciality oncology therapy
Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). This hematopoietic stem cell mobilizer is crucial for patients undergoing stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.
GLOBALSPECIALITYVENUSREMVIDHIINGChemicalsConsumer Services